# US 2024/0197723 A1 · Therapeutic compositions and methods for treating tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197723 A1
- Document ID: US20240197723A1
- Status: Published application
- Kind: A1
- Application number: 18/554,595
- Filed: 2022-04-07
- Published: 2024-06-20
- Earliest claimed: 2021-04-09
- Assignees: BeyondSpring Pharmaceuticals, Inc.
- Applicants: BeyondSpring Pharmaceuticals, Inc.
- Inventors: Lan Huang; Ramon Mohanlal; James R. Tonra
- Web page: https://patentgrep.com/patent/US20240197723A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are methods of treating, preventing or ameliorating a disease or condition associated with cancer or a tumor. In some embodiments, the method includes administering a compound of Formula (I) to a subject in need thereof wherein the cancer or the tumor is or becomes resistant to one or more immune checkpoint inhibitors.

## Claims

### Claim 1

A method of treating cancer in a subject, the method comprising:
administering to the subject a compound of Formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
R1, R4, and R6, are each separately selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and saturated C1,-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, —CO—O—R7, cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl —CH2CO—R7, wherein R7 is selected from a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups;
R1′ and R1″ are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, —CO—O—R7, cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl —CH2CO—R7, wherein R7 is selected from a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups;
R, R1′ and R1″ are either covalently bound to one another or are not covalently bound to one another;
R2, R3, and R5 are each separately selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, acyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, sulfonyl and substituted sulfonyl groups;
m is an integer equal to zero, one or two;
X1 and X2 are separately selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom, and
Y is selected from the group consisting of a NR5, an oxygen atom, a sulfur atom, a oxidized sulfur atom, a methylene group and a substituted methylene group;
Z, for each separate n, if non-zero, and Z1, Z2, Z3 and Z4 are each separately selected from a carbon atom, a sulfur atom, a nitrogen atom or an oxygen atom;
the dashed bonds may be either single or double bonds,
wherein the cancer was resistant to a prior treatment with one or more immune checkpoint inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer was a tumor that was resistant to the one or more immune checkpoint inhibitors.

### Claim 3 (depends on 2)

The method of claim 2, wherein the tumor progressed after the prior treatment with the one or more immune checkpoint inhibitors.

### Claim 4 (depends on 2)

The method of claim 2, wherein the tumor did not respond to an initial treatment regimen of the one or more immune checkpoint inhibitors.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, further comprising administering an additional chemotherapy agent.

### Claim 6 (depends on 5)

The method of claim 5, wherein the additional chemotherapy agent is administered before administering the compound of formula (I) to the subject.

### Claim 7 (depends on 5)

The method of claim 5, wherein the additional chemotherapy agent is a taxane.

### Claim 8 (depends on 7)

The method of claim 7, wherein the taxane is docetaxel.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein the one or more immune checkpoint inhibitor to which the cancer was resistant is a PD-1 inhibitor, PD-L1 inhibitor, a CTLA-4 inhibitor, or a combination thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the one or more immune checkpoint inhibitor to which the subject was resistant is a PD-1 inhibitor.

### Claim 11 (depends on 9)

The method of claim 9, wherein the one or more immune checkpoint inhibitor to which the subject was resistant is a PD-L1 inhibitor.

### Claim 12 (depends on 9)

The method of claim 9, wherein the one or more immune checkpoint inhibitor to which the subject was resistant is a CTLA-4 inhibitor.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the one or more immune checkpoint inhibitor to which the subject was resistant is pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, pembrolizumab, pidilizumab, ipilimumab, BMS 936559, durvalumab, spartalizumab, or any combinations thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the one or more immune checkpoint inhibitor to which the cancer was resistant is nivolumab and ipilimumab.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1 to 14, wherein the cancer is selected from a breast cancer, a bladder cancer, a glioma, a glioblastoma, a head and neck cancer, a non-small cell lung cancer, a small cell lung cancer, recurrent small cell lung cancer (SCLC), a colorectal cancer, a gastrointestinal stromal tumor, a gastroesophageal carcinoma, a renal cell cancer, a prostate cancer, a liver cancer, a colon cancer, a pancreatic cancer, an ovarian cancer, a lymphoma, or a cutaneous T-cell lymphoma, metastatic melanoma, hepatocellular carcinoma, malignant pleural mesothelioma, urothelial carcinoma, esophageal cancer, Merkel cell cancer, endometrial cancer, basal cell carcinoma, or a melanoma.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cancer is recurrent small cell lung cancer (SCLC).

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 to 16, further comprising co-administering to the subject an immune checkpoint inhibitor.

### Claim 18 (depends on 17)

The method of claim 17, wherein the co-administered one or more immune checkpoint inhibitor is a PD-1 inhibitor, PD-L1 inhibitor, a CTLA-4 inhibitor, or a combination thereof.

### Claim 19 (depends on 17)

The method of claim 17, wherein the co-administered one or more immune checkpoint inhibitor is pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, pembrolizumab, pidilizumab, ipilimumab, BMS 936559, durvalumab, spartalizumab, or any combinations thereof.

### Claim 20 (depends on 18)

The method of claim 18, comprising administering a PD-1 antibody and a CTLA-4 antibody.

### Claim 21 (depends on 20)

The method of claim 20, wherein the PD-1 antibody is nivolumab and the CTLA-4 antibody is ipilimumab.

### Claim 22 (depends on 21)

The method of claim 21, wherein the nivolumab is administered first followed by administering ipilimumab.

### Claim 23 (depends on 21)

The method of claim 21, wherein the nivolumab is administered on the same day as ipilimumab.

### Claim 24 (depends on 21)

The method of claim 21, wherein the nivolumab and the ipilmumab are administered on the same day every two weeks.

### Claim 25 (depends on 21)

The method of claim 21, wherein the nivolumab and the ipilmumab are administered on the same day every three weeks.

### Claim 26 (depends on 21)

The method of claim 21, wherein the nivolumab and the ipilmumab are administered on the same day every three weeks for four doses.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

The method of any one of claims 21 to 26, wherein the nivolumab is administered at a range from about 100 mg to 600 mg.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26)

The method of any one of claims 21 to 26, wherein the nivolumab is administered at a range from about 240 mg to 480 mg.

### Claim 29 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 17 to 28, wherein the co-administered one or more immune checkpoint inhibitor and the compound of Formula (I) is administered during four dosing cycles.

### Claim 30 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 17 to 28, wherein the subject receives the co-administered one or more immune checkpoint inhibitor and a compound of Formula (I) every 21-days.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1 to 30, further comprising administering radiation to the subject.

### Claim 32 (depends on 31)

The method of claim 31, wherein the radiation is administered before administering the compound of Formula (I) to the subject.

### Claim 33 (depends on 1)

The method of claim 1, further comprising administering a PD-1 or PD-L1 inhibitor and an additional chemotherapy agent to the subject.

### Claim 34 (depends on 1)

The method of claim 1, further comprising administering a PD-1 or PD-L1 inhibitor and radiation to the subject.

### Claim 35 (depends on 1)

The method of claim 1, further comprising administering a PD-1 or PD-L1 inhibitor and a CTLA-4 inhibitor to the subject.

### Claim 36 (depends on 1)

The method of claim 1, further comprising administering a CTLA-4 inhibitor and radiation to the subject.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1 to 36, wherein the compound of Formula (I) is administered at a dose from about 5 mg/m2 to 150 mg/m2.

### Claim 38 (depends on 37)

The method of claim 37, wherein the compound of Formula (I) is administered at a dose of about 20 mg/m2 to about 30 mg/m2.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1 to 38, wherein the compound of formula (I) is administered orally, sublingually, buccally, subcutaneously, intravenously, intranasally, intratumorally, topically, transdermally, intradermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, or intraocularly.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 1 to 39, wherein the compound of Formula (I) is administered on day 1 of a 14 day dosing cycle.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 1 to 39, wherein the compound of Formula (I) is administered on day 1 of a 21 day dosing cycle.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1 to 41, wherein the compound of Formula (I) is selected from plinabulin, (3Z,6Z)-3-(phenyl-2,3,4,5,6-d5)-methylene-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene)piperazine-2,5-dione; (3Z,6Z)-3-(phenyl-2,3,4,5,6-d5)-methylene-d-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene)piperazine-2,5-dione; (3Z,6Z)-3-(phenylmethylene-d)-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(phenyl-2,3,4,5,6-d5)-methylene-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(phenylmethylene)-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(phenyl-2,3,4,5,6-d5)-methylene-d-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(4-Fluoro-(phenyl-2,3,5,6-d4))-methylene-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene)piperazine-2,5-dione; (3Z,6Z)-3-(4-Fluoro-(phenyl-2,3,5,6-d4))-methylene-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(3-fluorobenzylidene)-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(3-benzoylbenzylidene)-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(3-(4-fluorobenzoyl)benzylidene)-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(3-(4-methoxybenzoyl)benzylidene)-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(3-methoxybenzylidene)-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; (3Z,6Z)-3-(3-(trifluoromethyenzydene)-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene-d)piperazine-2,5-dione; and a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1 to 42, wherein the compound of Formula (I) is plinabulin or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 2, 3, 4)

The method of any one of claims 2 to 4, wherein a mass of the tumor is reduced from about 50% to about 100%.

### Claim 45 (depends on 44)

The method of claim 44, wherein the tumor mass is reduced from about 50% to about 70%.

### Claim 46

A method of halting or reversing progressive cancer in a subject, the method comprising:
administering a compound of Formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
R1, R4, and R6, are each separately selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and saturated C1,-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, —CO—O—R7, cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl —CH2CO—R7, wherein R7 is selected from a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups;
R1′ and R1″ are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, —CO—O—R7, cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl —CH2CO—R7, wherein R7 is selected from a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups;
R, R1′ and R1″ are either covalently bound to one another or are not covalently bound to one another;
R2, R3, and R5 are each separately selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, acyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, sulfonyl and substituted sulfonyl groups;
m is an integer equal to zero, one or two;
X1 and X2 are separately selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom, and
Y is selected from the group consisting NR5, an oxygen atom, a sulfur atom, a oxidized sulfur atom, a methylene group and a substituted methylene group;
Z, for each separate n, if non-zero, and Z1, Z2, Z3 and Z4 are each separately selected from a carbon atom, a sulfur atom, a nitrogen atom or an oxygen atom;
the dashed bonds may be either single or double bonds,
wherein the subject was resistant to prior treatment with one or more immune checkpoint inhibitors.

### Claim 47

A method of treating cancer in a subject who exhibited resistance to checkpoint inhibitor therapy, the method comprising:
identifying a subject with a cancer that has shown resistance to one or more immune checkpoint inhibitors; and
co-administering to the subject plinabulin and one or more immune checkpoint inhibitors,
wherein the one or more immune checkpoint inhibitors is an inhibitor of PD-1, PD-L1 or CTLA-4.

### Claim 48 (depends on 47)

The method of claim 47, wherein the inhibitor of PD-1 is nivolumab and is administered at 1 mg/kg.

### Claim 49 (depends on 47)

The method of claim 47, wherein the inhibitor CTLA-4 is ipilimumab and is administered at 3 mg/kg.

### Claim 50 (depends on 47)

The method of claim 47, wherein the plinabulin is administered at a dose from about 13.5 mg/m2 to about 30 mg/m2 on day 1 of a 21 day cycle.
